ArticleBMC infectious diseases2014
Depolymerase improves gentamicin efficacy during Klebsiella pneumoniae induced murine infection.
Article in BMC infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- Phages as antimicrobials against multi-drug resistant bacteria.Frontiers in microbiology · 2026Review
- Phage vB_KpnM_JYSS3 encodes a novel polysaccharide depolymerase that exhibits specific activity against K2-type carbapenem-resistant Klebsiella pneumoniae.BMC microbiology · 2025Article
- Headway in Synthetic Chemistry: A Gateway for Antimicrobial Trojan Horse Strategy for Drug Repurposing Against Multi-Drug ResistantIndian journal of microbiology · 2025Review
- Analysis of a novel phage as a promising biological agent targeting multidrug resistant Klebsiella pneumoniae.AMB Express · 2025Article
- Review
- Pharmacokinetics and Biodistribution of Phages and their Current Applications in Antimicrobial Therapy.Advanced therapeutics · 2024Article
- Review
- Exploration of Antimicrobial Peptides in the Treatment of Gentamicin-ResistantInfection and drug resistance · 2024Article
- Effect of a Depolymerase Encoded by Phage168 on a Carbapenem-ResistantPathogens (Basel, Switzerland) · 2023Article
- Isolation and Characterization of the FirstInternational journal of molecular sciences · 2023Article
- Characterisation and sequencing of the novel phage Abp95, which is effective against multi-genotypes of carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2023Article
- Identification of a phage-derived depolymerase specific for KL47 capsule of Klebsiella pneumoniae and its therapeutic potential in mice.Virologica Sinica · 2022Article
- The Specific Capsule Depolymerase of Phage PMK34 SensitizesAntibiotics (Basel, Switzerland) · 2022Article
- Characterization and Functional Studies of a Novel Depolymerase Against K19-TypeFrontiers in microbiology · 2022Article
- Phage-Derived Depolymerase as an Antibiotic Adjuvant Against Multidrug-ResistantFrontiers in microbiology · 2022Article
- Phage φAB6-Borne Depolymerase CombatsAntibiotics (Basel, Switzerland) · 2021Article
- CAUTI's next top model - Model dependentBiofilm · 2020Article
- Isolation and Characterization of TwoInternational journal of molecular sciences · 2020Article
- Isolation of Four Lytic Phages InfectingInternational journal of molecular sciences · 2020Article
- Identification of a NovelFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPresence of capsule enhances the virulence of bacteria that cause pneumonia, meningitis, cystic fibrosis, dental caries, periodontitis. Capsule is an important virulence factor for Klebsiella pneumoniae and infections due to this pathogen have been associated with high mortality rates. In the present study, use of an Aeromonas punctata derived capsule depolymerase against K. pneumoniae, to reinstate the efficacy of gentamicin during pneumonia and septicemia was investigated.
methodsDepolymerase was administered in mice intraperitoneally (50 μg) alone as well in combination with gentamicin (1.5 mg/kg), 24 h post infection during acute lung infection and 6 h later during septicemia. Bacterial load, neutrophil infiltration and cytokine levels were estimated. The immunogenicity of protein was also studied.
resultsIn comparison to groups treated with gentamicin alone, combination treatment with depolymerase and gentamicin significantly reduced (P < 0.01) bacterial titer in the lungs, liver, kidney, spleen and blood of experimental animals. Highly significant reduction in neutrophil infiltration and levels of pro-inflammatory and anti-inflammatory cytokines was also observed. This indicated an efficient capsule removal by the enzyme, that improved gentamicin efficacy in vivo. Although the enzyme was found to be immunogenic, but no significant reduction in treatment efficacy was observed in the preimmunized as well as naïve mice. In addition, as confirmed through flow cytometry, the hyperimmune sera raised against the enzyme did not neutralize its activity.
conclusionThe results confirm that administration of enzyme 'depolymerase' along with gentamicin not only checked the virulence of K. pneumoniae in vivo but it also increased its susceptibility to gentamicin at a lower concentration. Such a strategy would help to avoid exposure to higher concentration of gentamicin. Moreover, since this decapsulating protein does not possess a lytic activity therefore there would be no chances of development of bacterial resistance against it. Therefore, it should be studied further for its successful inclusion in our prophylactic/therapeutic regimes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.